Pfizer announces $0.43 dividend for Q2 2025

NEW YORK - Pfizer Inc. (NYSE: PFE), the global biopharmaceutical company, has declared a quarterly cash dividend for the second quarter of 2025. The dividend of $0.43 per share is payable on June 13, 2025, to shareholders who are on record by the close of business on May 9, 2025. This marks the 346th consecutive quarter that Pfizer has distributed a dividend to its shareholders. According to InvestingPro data, the company currently offers a substantial 7.63% dividend yield and has maintained dividend payments for 55 consecutive years, demonstrating its commitment to shareholder returns.

The announcement reflects Pfizer’s ongoing commitment to return value to its investors while continuing its mission to develop and provide innovative medicines and vaccines. The company has a longstanding history in the pharmaceutical industry, with a focus on advancing wellness and prevention, as well as treatments for some of the most challenging diseases.

Pfizer’s dedication to quality, safety, and value in healthcare product development has been a cornerstone of its operations. The company has been instrumental in addressing healthcare needs across both developed and emerging markets, striving to improve the lives of patients worldwide.

As a leading entity in the biopharmaceutical sector, Pfizer collaborates with various stakeholders, including healthcare providers, governments, and communities, to ensure broad access to healthcare. This dividend declaration is a testament to the company’s stable financial performance and its ability to consistently provide shareholder value.

The information regarding the dividend is based on a press release statement from Pfizer Inc. Investors and interested parties can find additional details and updates about Pfizer’s financial activities on the company’s website.

Pfizer’s continued payment of dividends underscores its position in the industry and provides shareholders with a regular return on their investment. The company’s track record of consecutive dividend payments highlights its financial resilience and commitment to its shareholders.

In other recent news, Pfizer Inc. has announced the halt of its oral GLP-1 receptor agonist, danuglipron, intended for chronic weight management. This decision came after concerns over potential drug-induced liver injury, despite the drug meeting its primary goals in dose optimization studies. Pfizer’s move is seen as a setback in its efforts to compete in the obesity treatment market, leading analysts like those from Bernstein and Leerink to maintain their Market Perform ratings, with price targets of $30 and $28, respectively. Additionally, UBS has adjusted its price target for Pfizer shares down to $24 from $28, citing concerns over the impact of the Inflation Reduction Act on Pfizer’s portfolio and potentially optimistic sales estimates for products like Paxlovid and Comirnaty.

Meanwhile, Morgan Stanley has reiterated its Equalweight rating with a $31 price target, highlighting Pfizer’s continued commitment to exploring internal and external opportunities in obesity treatments. Pfizer is also advancing the development of an oral GIPR antagonist candidate, PF-07976016, with Phase 2 results expected by December 2025. Furthermore, Pfizer’s shares, along with other major pharmaceutical companies, have experienced pressure following President Donald Trump’s announcement of potential tariffs on the industry. These tariffs are intended to encourage pharmaceutical companies to shift operations back to the United States, raising concerns about increased costs and potential disruptions in the global supply chain.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.